Comparisons Semaglutide vs Orforglipron

Semaglutide vs Orforglipron

Side-by-side comparison of weight loss results, pricing, side effects, and clinical data.

Semaglutide

~15%

Orforglipron

~14%

Head-to-Head Comparison

Metric
SemaglutideOzempic / Wegovy
OrforglipronNot yet approved (Eli Lilly)
Drug Class
GLP-1 RA (peptide)
GLP-1 RA (small molecule, oral)
Administration
Weekly injection
Daily oral tablet
Dosing
Once weekly
Once daily
Avg. Weight Loss
~15%
~14%
Half-Life
~7 days
~29 hours
Compounded Cost
$150-400/mo (compounded)
Not yet available
Brand Cost
$1,000-1,400/mo
Not yet available (expected to be cheaper than injectables)
FDA Approved
2021
—
Key Trial
STEP 1 (16.9% weight loss)
Phase 2 (up to 14.7% weight loss at 36 weeks)

Side Effects Comparison

Semaglutide

  • Nausea
  • Diarrhea
  • Vomiting

Orforglipron

  • Nausea
  • Diarrhea
  • Vomiting

Pros & Cons

Semaglutide

Pros

  • +FDA-approved and available now
  • +Extensive safety data
  • +Proven cardiovascular benefits

Cons

  • -Requires injection
  • -Peptide-based (cold chain required)
  • -Expensive at brand pricing

Orforglipron

Pros

  • +Oral pill (no injections)
  • +Small molecule (easier to manufacture, no cold chain)
  • +May be cheaper to produce at scale

Cons

  • -Not yet approved
  • -Slightly less weight loss in early data
  • -Daily dosing required

The Verdict

Orforglipron could be a game-changer as an oral small-molecule GLP-1 that approaches injectable semaglutide's weight loss (~14% vs ~15%). Unlike Rybelsus (oral semaglutide), orforglipron is a small molecule that is easier and cheaper to manufacture. If approved, it could dramatically lower the cost of GLP-1 therapy and eliminate the need for injections.

No head-to-head trials yet. Phase 3 trials (ACHIEVE program) are underway.

Which Is Right for You?

Choose Semaglutide if...

Patients who need effective treatment available today

Choose Orforglipron if...

Future option for patients who want injectable-level results from a daily pill

Frequently Asked Questions

When will orforglipron be available?

Eli Lilly is conducting Phase 3 trials (ACHIEVE program). If successful, FDA approval could come in 2026-2027. It would be the first oral small-molecule GLP-1 for obesity.

How is orforglipron different from Rybelsus?

Rybelsus is oral semaglutide (a peptide that needs special absorption enhancement and fasting). Orforglipron is a small molecule — it absorbs more easily, doesn't require fasting, and is much cheaper to manufacture.

Could orforglipron make GLP-1s affordable?

Potentially, yes. Small molecules are far cheaper to produce than peptides. Without cold chain requirements and with simpler manufacturing, the cost could be significantly lower than current injectable GLP-1s.

Find a provider prescribing Semaglutide or Orforglipron

Compare pricing, reviews, and availability across 18,000+ GLP-1 providers nationwide.

Search Providers →

View all GLP-1 comparisons

Compare every major GLP-1 medication side by side. Weight loss data, cost analysis, and clinical trial results.

All Comparisons →